Divi's Lab Results Analysis

Q4FY25 – Operating Revenue Rs. 2,585 Cr. 12% Growth YoY, EBITDA Rs. 886 Cr. 21% Growth YoY, EBITDA Margin 34.3% 253 bps Growth YoY, Profit before tax (PBT) Rs. 864 Cr. 21% Growth YoY, Profit after tax (PAT) Rs. 662 Cr. 23% Growth YoY. FY25 – Operating Revenue Rs. 9,360 Cr. 19% Growth YoY, EBITDA Rs. 2,968 Cr. 34.6% Growth YoY, EBITDA Margin 31.7% 360 bps Growth YoY, Profit before tax (PBT) Rs. 2,916 Cr. 34.8% Growth YoY, Profit after tax (PAT) Rs. 2,191 Cr. 36.9% Growth YoY FY25, generics contributed 46% to revenue (49% in Q4), with custom synthesis at 54% (51% in Q4). Exports: 88% of sales (Europe + US: 73% in FY25 vs 70% in FY24). Double-digit revenue growth targeted for FY26 and beyond. The Board declared Final dividend of Rs. 30 per Equity Share.